Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of dual-modality ablation for symptomatic cystic thyroid nodules.

Gland surgery·2026
Same author

Rare But Risky: Clinical Impacts of Pneumothorax After Thyroidectomy and Parathyroidectomy.

The Laryngoscope·2026
Same author

Beyond levothyroxine: a narrative review of adjunctive management strategies for Hashimoto's thyroiditis.

Gland surgery·2026
Same author

Impact of cervical thymectomy on multiple endocrine neoplasia type 1 patients undergoing parathyroidectomy for primary hyperparathyroidism.

Surgery·2026
Same author

[Corrigendum] Tumor necrosis factor‑α triggers opposing signals in head and neck squamous cell carcinoma and induces apoptosis via mitochondrial‑ and non‑mitochondrial‑dependent pathways.

International journal of oncology·2026
Same author

Safety and efficacy of radiofrequency ablation of benign thyroid nodules in patients with a history of implantable cardioverter defibrillators (ICDs), permanent pacemakers (PPMs), and implantable cardiac monitors (ICMs).

Gland surgery·2026

Related Experiment Video

Updated: May 18, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

BRAF mutation in papillary thyroid carcinoma.

Xinying Li1, Asim B Abdel-Mageed, Emad Kandil

  • 1Department of Surgery, Tulane University, School of medicine New Orleans, LA, USA.

International Journal of Clinical and Experimental Medicine
|September 21, 2012
PubMed
Summary
This summary is machine-generated.

BRAF mutations are common in papillary thyroid cancer (PTC), driving tumor growth. Detecting these BRAF mutations in fine-needle aspiration (FNA) aids diagnosis and treatment decisions for PTC.

Keywords:
BRAF mutationBRAF/MAPK signaling pathwaypapillary thyroid carcinomatargeting therapy

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Experiment Videos

Last Updated: May 18, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • BRAF mutations are the most frequent genetic alterations in thyroid cancer, especially papillary thyroid cancer (PTC).
  • The BRAF/MAPK signaling pathway, when excessively activated by BRAF mutations, is crucial for PTC tumorigenesis and progression.
  • BRAF mutation is linked to unfavorable clinicopathological features in PTC, highlighting its significance.

Purpose of the Study:

  • To summarize the role of BRAF mutations in papillary thyroid cancer.
  • To emphasize the diagnostic and prognostic value of BRAF mutation detection in fine-needle aspiration (FNA) specimens.
  • To review the development of targeted therapies for BRAF-mutated PTC.

Main Methods:

  • Literature review of studies on BRAF mutations in thyroid cancer.
  • Analysis of the association between BRAF mutations and PTC characteristics.
  • Overview of diagnostic and therapeutic strategies.

Main Results:

  • BRAF mutations are a key driver in PTC development and progression.
  • Preoperative BRAF mutation detection in FNA specimens is a valuable tool for PTC diagnosis and prognosis.
  • Targeted therapies inhibiting BRAF activation are emerging as a treatment option.

Conclusions:

  • BRAF mutation is a critical factor in PTC, influencing clinical management.
  • Early detection of BRAF mutations via FNA improves patient care and treatment planning.
  • Targeted BRAF inhibition represents a promising therapeutic avenue for PTC.